Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Analyst Lowers Merck Estimates

November 11, 2011 5:44 am | News | Comments

The drugmaker Merck & Co.'s long-term sales and earnings growth is unsustainable without more business development to supplement its pipeline, according to a Citi analyst.


The Force Within You Discovered by Chemists

November 10, 2011 11:53 am | News | Comments

A method for visualizing mechanical forces on the surface of a cell provides a detailed view of those forces, as they occur in real-time.

Positive Results for Type 2 Diabetes

November 10, 2011 11:50 am | News | Comments

A randomized, placebo-controlled study was performed in 17 non-human primates with dietary-induced Type 2 diabetes to evaluate the effects of a single intravenous injection of Mesoblast's allogeneic, Mesenchymal Precursor Cells on blood glucose levels over an eight week period.


Signum, GlaxoSmithKline Enter Agreement

November 10, 2011 11:46 am | News | Comments

Signum Biosciences Inc. will collaborate with GlaxoSmithKline on Signum's phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A).


Experimental Drug Helps Obese Monkeys Lose Weight

November 10, 2011 11:44 am | News | Comments

Obese rhesus monkeys lost an average of 11% of their body weight after four weeks of treatment with an experimental drug that selectively destroys the blood supply of fat tissue.

RNA Visualization Probes

November 10, 2011 11:40 am | Product Releases | Comments

Biosearch Technologies Inc.’s Stellaris Fish Probes are an RNA visualization method that allows detection, localization, and quantification of individual mRNA molecules at the sub-cellular level in fixed samples.


Luminescence Assay Plate

November 10, 2011 11:35 am | Product Releases | Comments

Constructed in pure grade polystyrene, the Krystal 2000 plate from Porvair Sciences is designed for luminescence applications that require photometric accuracy and repeatability.


Live Cell Imaging Software

November 10, 2011 11:27 am | Product Releases | Comments

TAP Biosystems’ Cell-IQ software comes with two plate positions that allow cells to be to be maintained for days or weeks, side by side in normoxia. Researchers can train the system to recognize experimental characteristics including cell attachment phases, scratch wound proliferation and migration assays.


Desalted DNA Oligonucleotides

November 10, 2011 7:45 am | Product Releases | Comments

Integrated DNA Technologies now offers its customers the ability to order RxnReady oligonucleotides. Users can specify the premixing of 2 – 6 standard desalted DNA oligos, in a single tube, according to the individual specifications provided.


Real-Time PCR System

November 10, 2011 7:39 am | Product Releases | Comments

Thermo Fisher Scientific Inc. has introduced its PikoReal Real-Time PCR Systems, which complete its molecular biology workflow. Available in 24- and 96-well formats, the PikoReal offers performance in a small bench-top footprint.


MPI VP Serota Elected ACT President

November 10, 2011 6:58 am | News | Comments

MPI Research has announced that David Serota, PhD, DABT, senior vice president of drug safety development and senior principal study director, will serve as the 2012 American College of Toxicology president.

Merck Launches Birth Control Implant

November 10, 2011 6:54 am | News | Comments

Merck & Co. said it has launched the long-acting birth control implant Nexplanon in the United States. Nexplanon has been approved by the Food and Drug Administration for the prevention of pregnancy in women for up to three years.


FDA Accepts Vismodegib NDA

November 10, 2011 6:49 am | News | Comments

Genentech announced that the U.S. Food and Drug Administration has accepted and filed the company’s New Drug Application for vismodegib for the treatment of adults with advanced basal cell carcinoma for whom surgery is considered inappropriate.


Sinovac Reports Phase 2 Trial Results

November 10, 2011 6:19 am | News | Comments

Sinovac Biotech Ltd. announced positive top-line results from its Phase 2 clinical trial for its inactivated vaccine against human enterovirus 71, which causes hand, foot and mouth disease.


Merck to Seek Approval for 8 New Drugs

November 10, 2011 6:14 am | News | Comments

Merck & Co. plans in the next two years to seek U.S. approval for eight new medicines and has other promising drugs in late-stage testing, including drugs for chronic insomnia, hardening of the arteries, osteoporosis, and reversal of anesthesia.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.